The clinical significance of palivi-zumab in the prevention of severe respiratory infections in newborn infants

Palivizumab is known as the world''s first drug with proven efficacy for passive immunization of severe infections of lower respiratory tract in preterm infants. The paper describes a clinical case of application of palivizumab (sinagis) at a newborn infant with bronchopulmonary dysplasia complicated by episodes of obstructive bronchitis. Particular attention is paid to the mechanism of action of palivizumab on the respiratory syncytial virus providing the data on a clinical picture of respiratory syncytial virus infection in a premature baby and showing the effectiveness of the drug in infants.